Explore in detail how the pharmaceutical companies perform on Access to Medicine Index and AMR Benchmark

Compare companies
1 1
GSK plc
0 1 2 3 4 5
4.06
2 3
Johnson & Johnson
0 1 2 3 4 5
4.03
3 7
AstraZeneca plc
0 1 2 3 4 5
3.93
4 2
Novartis AG
0 1 2 3 4 5
3.87
5 8
Merck KGaA
0 1 2 3 4 5
3.72
6 4
Pfizer Inc
0 1 2 3 4 5
3.62
7 6
Takeda Pharmaceutical Co, Ltd
0 1 2 3 4 5
3.51
8 5
Sanofi
0 1 2 3 4 5
3.47
9 13
Bayer AG
0 1 2 3 4 5
3.36
10 9
Roche Holding AG
0 1 2 3 4 5
3.23
11 10
Novo Nordisk A/S
0 1 2 3 4 5
2.97
12 11
Eisai Co, Ltd
0 1 2 3 4 5
2.95
13 12
Boehringer Ingelheim
0 1 2 3 4 5
2.93
14 14
Gilead Sciences
0 1 2 3 4 5
2.84
15 19
Bristol Myers Squibb
0 1 2 3 4 5
2.60
16 14
Astellas Pharma Inc
0 1 2 3 4 5
2.46
17 16
Daiichi Sankyo Co, Ltd
0 1 2 3 4 5
2.20
18 15
Merck & Co, Inc
0 1 2 3 4 5
2.15
19 17
AbbVie Inc
0 1 2 3 4 5
1.84
20 18
Eli Lilly & Co
0 1 2 3 4 5
1.79
0 1 2 3 4 5

In the 2021 Index, dense ranking was used. In the 2022 Index, standard competitive ranking is used. Therefore, a direct comparison with the previous ranks of AbbVie, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Merck & Co, Inc (MSD) is not possible.

The ranking above shows the position and score of each company in the 2022 Index (left) and 2021 Index (right). Click on a company's name to go to its full report card.